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ABSTRACT
Bovine milk glycomacropeptide (GMP) is derived 
from κ-casein, with exclusively o-linked glycosylation. 
Glycomacropeptide promoted the growth of Bifidobacte-
rium longum ssp. infantis in a concentration-dependent 
manner, and this activity was lost following periodate 
treatment of the GMP (GMP-P), which disables bio-
logical recognition of the conjugated oligosaccharides. 
Transcriptional analysis of B. longum ssp. infantis fol-
lowing exposure to GMP revealed a substantial response 
to GMP relative to bacteria treated with GMP-P, with 
a greater number of differentially expressed transcripts 
and larger fold changes versus the control. Therefore, 
stimulation of B. longum ssp. infantis growth by GMP 
is intrinsically linked to the peptide’s O-linked glycosyl-
ation. The pool of differentially expressed transcripts 
included 2 glycoside hydrolase (family 25) genes, which 
were substantially upregulated following exposure to 
GMP, but not GMP-P. These GH25 genes were present 
in duplicated genomic islands that also contained genes 
encoding fibronectin type III binding domain proteins 
and numerous phage-related proteins, all of which were 
also upregulated. Homologs of this genomic arrange-
ment were present in other Bifidobacterium species, 
which suggest it may be a conserved domain for the 
utilization of glycosylated peptides. This study provides 
insights into the molecular basis for the prebiotic effect 
of bovine milk GMP on B. longum ssp. infantis.
Key words: glycomacropeptide, Bifidobacterium, 
bovine milk, transcription
INTRODUCTION
A bifidobacteria-rich microbiome has numerous bio-
logical benefits to the host, including maintenance of 
a healthy gastrointestinal tract, inhibition of microbial 
infection, and alleviating symptoms associated with 
digestive illness (Leahy et al., 2005; Picard et al., 
2005). Therefore, interest is growing in enhancing the 
bifidobacterial population of the gastrointestinal tract. 
Human milk oligosaccharides (HMO) represent the 
main impetus for bacterial colonization of the distal 
large intestine of the breast-fed infant (Scholtens et al., 
2012). The high concentrations of HMO and oligosac-
charides either N- or O-linked to proteins processed 
after intestinal digestion are thought to be the main 
contributors to the predominance of Bifidobacterium 
species in the infant gut (Garrido et al., 2013a). Indeed, 
the genome of one particular strain, Bifidobacterium 
longum ssp. infantis ATCC15697, a common member 
of the gastrointestinal microbiota of breast-fed infants, 
has revealed particular adaptations for the metabolism 
of HMO (LoCascio et al., 2007, 2010; Sela et al., 2008, 
2011, 2012; Garrido et al., 2011, 2012b; Kim et al., 
2013), milk glycoconjugates (Garrido et al., 2013a), 
and even commercial oligosaccharides such as galacto-
oligosaccharides (Garrido et al., 2013b), and fructo-
oligosaccharides (Perrin et al., 2001). In particular, the 
strain consumes these various carbohydrates using a 
variety of glycosyl hydrolases and ABC transporters 
(Sela et al., 2008; Garrido et al., 2013a).
However, the large quantities of HMO required for 
use as functional ingredients are unavailable, whereas 
commercial oligosaccharides such as galacto-oligosac-
charides and fructo-oligosaccharides and individual 
HMO cannot match the complexity of the HMO pool 
present in breastmilk in terms of biological benefits. 
Bovine milk is potentially an alternative source of com-
plex oligosaccharides with associated biological activ-
ity. However, the concentration and number of oligosac-
charides is much lower than that of human milk, and 
currently the large quantities required are commercially 
unavailable. Certain glycoconjugates present in bovine 
milk have been purified at a large scale, as previously 
reviewed (O’Riordan et al., 2014), and may offer an 
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alternative source of functional oligosaccharides. Karav 
et al. (2016) recently demonstrated the ability of bifi-
dobacteria to use N-linked glycan chains cleaved from 
bovine milk glycoproteins as growth promoting factors 
and different bifidobacterial strains selectively con-
sumed varying glycan structures.
Of the glycosylated proteins present in bovine milk, 
glycomacropeptide (GMP), a 64-AA peptide derived 
from κ-CN (Delfour et al., 1965), offers great poten-
tial as a functional food ingredient. Importantly, GMP 
can be produced in the quantities required for use as 
a food ingredient (Tullio et al., 2007) and it is com-
mercially available as an ingredient for application in 
functional and medical foods, beverages, cosmetics, and 
supplements (O’Riordan et al., 2014; Ney et al., 2016). 
Glycomacropeptide has been formulated into medical 
foods for the treatment of phenylketonuria (Ney et al., 
2016; Ney and Etzel, 2017) and has been shown to im-
prove the growth of lactobacilli and bifidobacteria and 
enhance microbial diversity, both in vitro (Janer et al., 
2004; Robitaille, 2013; Ntemiri et al., 2017) and in vivo 
(Chen et al., 2012; Sawin et al., 2015). Several other 
biological benefits have also been associated with GMP, 
including anti-infective (Nakajima et al., 2005; Gustavo 
Hermes et al., 2013) and antitoxigenic (Kawasaki et al., 
1992; Isoda et al., 1989) activities. The carbohydrate 
content of bovine GMP is known to play a role in many 
of its associated biological benefits (O’Riordan et al., 
2014).
However, reports are conflicting on the importance 
of the carbohydrate content of GMP in relation to the 
growth promotion of bifidobacteria, with recent studies 
suggesting that only the peptide backbone of CMP was 
essential for prebiotic activity (Robitaille, 2013). In the 
present work, the growth- and metabolic-related tran-
scriptomic changes of an archetypical infant B. longum 
ssp. infantis strain following transient exposure to 
GMP is reported. The oligosaccharides on GMP were 
oxidized using sodium metaperiodate to investigate the 
role of GMP glycosylation. The observed phenotypic 
changes were subsequently correlated with transcrip-
tional changes as determined by microarray analysis.
MATERIALS AND METHODS
Materials
Glycomacropeptide, with a maximum assayed lactose 
content of 1%, was provided by Agropur Ingredients, 
(Eden Prairie, MN). Vivaspin 6 centrifugal filters with 
a 3-kDa molecular weight cutoff were purchased from 
Sartorius Stedim Biotech GmbH (Göttingen, Germa-
ny). Bifidobacterium longum ssp. infantis ATCC 15697 
was purchased from DSMZ (Braunschweig, Germany). 
de Man, Rogosa, Sharpe (MRS) broth was purchased 
from Oxoid Ltd. (Basingstoke, UK). The Anaerocult 
A system was purchased from Merck (Dannstadt, Ger-
many). All other reagents were from Sigma-Aldrich Co. 
(Dublin, Ireland), unless otherwise stated, and were of 
the highest grade available.
Periodate Treatment of GMP
Sodium metaperiodate (NaIO4) treatment of GMP 
(GMP-P) was performed as previously described 
(Alemka et al., 2010). Briefly, GMP (2 mg/mL) was 
incubated with 0.011 mM NaIO4 (Alemka et al., 2010) 
at 4°C for 30 min. Excess NaIO4 was removed by cen-
trifugal filtration using a 3-kDa molecular weight cutoff 
with 3 PBS, pH 7.4 washes and the retentate contain-
ing GMP-P was lyophilized.
Bacterial Culture and Growth Experiments
Bifidobacterium longum ssp. infantis was routinely 
cultured in MRS supplemented with 0.05% wt/vol l-
cysteine (mMRS) at 37°C under anaerobic conditions 
generated using the Anaerocult A system (Kavanaugh 
et al., 2013). Bacterial culture stocks were maintained 
in mMRS containing 50% vol/vol glycerol at −80°C 
and propagated twice in mMRS medium before use. 
Bacterial growth assays were performed in mMRS sup-
plemented with increasing concentrations of GMP (0.5, 
1, 2, 4, and 8 mg/mL) and filter sterilized through a 
0.22-µm membrane. The medium was inoculated with a 
1% vol/vol inoculation of an overnight culture with an 
optical density at 600 nm (OD600nm) of approximately 
1.0 (corresponding to approximately 2 × 108 cfu/mL). 
Cultures entered midexponential phase of growth af-
ter 16 h, and OD600nm values at this time point were 
taken for comparison between each treatment. Growth 
experiments were performed in triplicate and the data 
presented is the average of 3 independent replicate as-
says. The OD600nm was measured on a PharmaSpec UV-
1700 UV-visible spectrophotometer (Shimadzu, Kyoto, 
Japan).
RNA Isolation
Bifidobacterium longum ssp. infantis was cultured 
to midexponential phase in mMRS as a control and 
mMRS supplemented with GMP or GMP-P (2 mg/
mL) and bacterial pellets were harvested by centrifuga-
tion at 4,500 × g for 8 min at 4°C. The supernatant 
was removed and the bacterial pellets were resuspended 
in RNAprotect bacteria reagent (Qiagen, Hilden, Ger-
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many) and incubated at room temperature for 10 min. 
Bacteria were again pelleted at 5,000 × g for 10 min 
and the supernatant was discarded. Bacterial RNA was 
isolated using the RNA isolate mini kit (Bioline, Lon-
don, UK) with modifications, as previously described 
(Kavanaugh et al., 2013). The RNA quantity and qual-
ity was determined using a NanoDrop 1000 (Thermo 
Fisher, Wilmington, DE), and products with 260/280 
nm readings >1.9 and 230/260 nm readings ≥1.00 were 
selected for further analysis. Sample quality was fur-
ther assessed by agarose gel electrophoresis. The RNA 
samples were subsequently shipped to IMGM labora-
tories (Martinsried, Germany) for labeling and DNA 
microarray analysis. To ensure the absence of RNA 
degradation during transit, RNA was again assessed 
using an Agilent Bioanalyser (RNA600 Chip; Agilent 
Technologies, Co. Cork, Ireland) and only samples with 
a RNA integrity number (RIN) of 10 were approved for 
microarray analysis.
Microarray Analysis
The RNA was spiked with synthetic polyadenylated 
transcripts (Agilent spike-in controls) and labeled by a 
protocol for reverse transcription followed by in vitro 
transcription. In brief, 500 ng of RNA was used for each 
reaction, which was reversed transcribed into cDNA 
using random priming (Full SpectrumTM MultiStart 
Primers for T7 IVT, System Biosciences, Palo Alto, 
CA). This was then converted into labeled cRNA by 
in vitro transcription (Quick-Amp Labeling Kit One-
Color, Agilent Technologies) incorporating cyanine 3 
(Cy3)-conjugated CTP. Manufacturer’s instructions 
(https:// www .agilent .com/ cs/ library/ usermanuals/ 
Public/ G4140 -90040 _GeneExpression _OneColor _6 .9 
.pdf) were followed for both the reverse transcription 
and labeling reactions.
A NanoDrop analyzer and an Agilent 2100 Bioanaly-
ser with a 6000 Nano LabChip Kit (Agilent Technolo-
gies) were employed to determine the labeling efficacy 
and samples with cRNA yields >825 ng and a specific 
activity of 9.0 pmol of Cy3/µg of cRNA were selected 
for array analysis. Following cRNA clean-up and quan-
tification (Thermo Fisher), 600 ng of each Cy3-labeled 
cRNA sample was fragmented and prepared for One-
Color based hybridization (Gene Expression Hybrid-
ization Kit, Agilent Technologies). Hybridization was 
performed at 65°C for 17 h on custom Bifidobacterium 
GE Microarrays (8 × 15K format) as per Kavanaugh 
et al. (2013), which were then washed with increasing 
stringency using Gene Expression Wash Buffers (Agi-
lent Technologies) followed by drying with acetonitrile. 
Fluorescent signal intensities were detected with Scan 
Control A.8.4.1 Software (Agilent Technologies) on 
the Agilent DNA Microarray Scanner and extracted 
from the images using Feature Extraction 10.7.3.1 
Software (Agilent Technologies) and the design file 
033172_D_F_20110831.xml.
Quantitative Real-Time PCR Analysis
Complementary DNA was synthesized from 1 µg of 
RNA (isolated as described above) as per Kavanaugh 
et al. (2013). Template and random primers were in-
cubated at 65°C for 10 min, followed by addition of 
the remaining components. The reaction mixture was 
then incubated at 55°C for 30 min and inactivated 
by heating to 85°C for 5 min. The PCR primers and 
probes were designed using the Universal Probe Library 
Assay Design Centre (Roche, Basel, Switzerland). 
Primer sequences and probe combinations are listed in 
Supplemental Table S1 (https:// doi .org/ 10 .3168/ jds 
.2018 -14499). The 16S rRNA (Blon_R0085) was used 
as an endogenous control to correct for variability in 
the starting total RNA and provide a stable expression 
marker against which relative levels of expression were 
determined. Amplification reactions were performed in 
duplicate as per Kavanaugh et al. (2013). The 2−ΔΔCt 
method (Livak and Schmittgen, 2001) was employed to 
calculate relative changes in gene expression.
Computer Analysis
The DNA sequence analyses and homology searches 
were carried out using the NIH BLAST program 
(Altschul et al., 1990).
Statistical Analysis
The microarray data were processed using the 
Limma package of the R statistics suite (http:// www 
.R -project .org). Background correction was done us-
ing the normexp method with offset = 16. Interarray 
normalization was not done. The microarray data were 
clustered using the heatmap.2 package in R to identify 
any experimental samples as outliers. The fold change 
values presented are actual fold change values for the 
test samples relative to the controls. Genes with a fold 
change of >1.5 where P ≤ 0.05 were considered to be 
differentially transcribed. Transcriptional changes were 
displayed graphically through the use of Volcano plots 
(−log10 P-value vs. log2 fold-change) and whole genome 
plots, where the fold change for each locus tag was 
plotted as a bar chart.
The statistical treatment of the quantitative real-
time PCR (RT-qPCR) data was by Student’s t-test 
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and one-way ANOVA for pairwise or multiple compari-
sons, respectively, to determine statistically significant 
results, where P < 0.05 was considered significant.
RESULTS AND DISCUSSION
Effect of GMP on B. longum ssp. infantis Growth
To investigate if GMP had a prebiotic effect on the 
archetypal infant associated bifidobacterial strain, B. 
longum ssp. infantis was cultured in mMRS supple-
mented with 2 mg/mL of GMP, as this concentration 
has been proven to positively influence the growth of 
probiotic strains Lactobacillus rhamnosus RW-9595-M 
and Bifidobacterium thermophilum RBL67 (Robitaille, 
2013). Higher concentrations are also unlikely to occur 
in biological conditions in vivo, as levels of 1.2 to 1.5 
mg/mL are found in cheese whey, which is almost 10 
times higher than free GMP in mature milk (Furlanetti 
and Prata, 2003; Neelima et al., 2013). A 20.6 ± 3.6% 
increase in OD600nm was observed in the midexponential 
phase of B. longum ssp. infantis cultures supplemented 
with GMP, indicating a growth promoting effect (Fig-
ure 1A). Assays were repeated with increasing GMP 
concentrations and OD600nm was recorded after 16 h of 
incubation, at the midexponential phase. A concentra-
tion-dependent growth–promoting effect was observed 
(Figure 1B), with the most significant effect (an in-
crease of 44 ± 9.9% versus the control) observed using 
8 mg/mL of GMP. A concentration of 2 mg/mL of 
GMP was chosen for the remainder of the study, as this 
concentration was used in previous studies (Robitaille, 
2013) and correlates with the concentration of GMP 
present in cheese manufacturing whey (1.2–1.5 mg/mL; 
Neelima et al., 2013).
Addition of 2 mg/mL of oxidized GMP-P resulted 
in a substantially lower (5.5%) increase in growth 
compared with that following addition of 2 mg/mL 
of GMP (20.6%; Figure 1C). Periodate oxidation of 
glycoproteins converts vicinal diols of oligosaccharide 
residues to 2 aldehyde groups, making the carbohy-
drate structures biologically unrecognizable (Kilcoyne 
et al., 2011). Following periodate treatment of GMP, a 
decrease of approximately 75% in the growth promo-
tion effect of the glycopeptide was observed. A slight 
growth increase was still evident in the GMP-P group, 
indicating that the peptide portion may also influence 
bacterial growth. Overall, this data suggests that GMP 
glycosylation has a very important role to play in the 
promotion of B. longum ssp. infantis growth.
Glycomacropeptide is exclusively O-glycosylated 
with both neutral and acidic oligosaccharides (Saito, 
1980; Saito et al., 1981a,b, 1982; Kawasaki et al., 1993). 
Sialic acid is a prominent feature of these glycans, with 
82% of GMP oligosaccharides being either mono- or 
disialylated (Hua et al., 2012). This high sialic acid 
content may be the basis for the prebiotic activity de-
scribed for GMP, as prebiotic activity has previously 
been linked to other sialic acid containing compounds 
(Idota et al., 1994).
Figure 1. (A) Growth of Bifidobacterium longum ssp. infantis in 
de Man, Rogosa, and Sharpe broth supplemented with 0.05% wt/vol 
l-cysteine (mMRS) with (gray) and without (black) supplementation 
with 2 mg/mL of bovine glycomacropeptide (GMP) over 24 h. (B) 
Percent increase in optical density at 600 nm (OD600nm) of B. longum 
ssp. infantis cultured in the presence of increasing concentrations of 
GMP versus unsupplemented mMRS at mid-exponential phase. (C) 
Comparison of the percent increase in OD600nm of B. longum ssp. in-
fantis cultured in the presence of 2 mg/mL of GMP or periodate treat-
ment of the GMP (GMP-P) versus unsupplemented mMRS at mid-
exponential phase. Error bars indicate ± SD.
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Gene Expression Analysis
Bifidobacterium longum ssp. infantis was cultured 
to midexponential phase in MRS, MRS + GMP (2 
mg/mL), and MRS + GMP-P (2 mg/mL) and bac-
teria were harvested for microarray analysis to profile 
gene expression in response to the presence of GMP 
or GMP-P in the growth medium versus the control 
(MRS only). The data were submitted to Gene Ex-
pression Omnibus (GEO) functional genomics data 
repository (Edgar et al., 2002), and assigned accession 
number GSE75969 with the array platform designated 
GPL21235. The overall number of genes differentially 
expressed following GMP supplementation is summa-
rized in Figure 2A, and a complete list of differentially 
expressed transcripts (DET) is provided in Supplemen-
tal Table S2 (https:// doi .org/ 10 .3168/ jds .2018 -14499). 
The largest collection of DET were upregulated by 
GMP (264 genes), whereas considerably fewer genes 
were found to be downregulated (47 genes); 153 DET 
were upregulated by GMP-P and none were downregu-
lated. The DET were categorized into groups based on 
their annotated function as genes involved in glycan 
metabolism, cellular transport, protein metabolism, 
cell division and growth, and hypothetical, or proteins 
of unknown function and other (Figure 2B). With the 
exception of the hypothetical protein category, genes 
involved in cell division were the largest population of 
DET, which is not surprising considering the observed 
growth promotion effect of GMP.
In total, 56 genes were shared between both GMP 
and GMP-P treatments (Figure 2A), with the majority 
of the annotated genes in this population involved in 
noncarbohydrate-related transport and cell growth, as 
outlined in Supplemental Table S2 (https:// doi .org/ 10 
.3168/ jds .2018 -14499). A cluster of phosphonate ABC 
Figure 2. (A) Number of differentially expressed transcripts following exposure to glycomacropeptide (GMP) or oxidized periodate treat-
ment of the GMP (GMP-P). The cutoff point for inclusion was fold change ≥1.5 and P ≤ 0.05. Black = upregulated versus control. Gray = 
downregulated versus control. (B) Numbers of Bifidobacterium longum ssp. infantis genes, grouped according to functional category, which were 
differentially regulated following growth in the presence of GMP or GMP-P. Black bars indicated the number of genes that were common to 
both treatments.
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transporter genes (Blon_0020-Blon_0025), as well as 
numerous other transport-related genes, were upregu-
lated by both treatments and may give insight into the 
effect of GMP on nutrient uptake by B. infantis from 
the environment. When the genome of B. infantis was 
first published in 2008, 35% of the ORFs in B. longum 
ssp. infantis were annotated as hypothetical proteins, 
which comprised 845 proteins of unknown function 
(Sela et al., 2008). The majority of these genes are still 
currently annotated as hypothetical, and this category 
represented the largest group of genes influenced by 
exposure to GMP and GMP-P, indicating the need for 
further functional genomic studies to elucidate the role 
of specific genes. Volcano plots (Figure 3) provide a 
graphic representation of the greater magnitude of the 
transcriptomic response to GMP treatment when com-
pared with GMP-P. Although both treatments resulted 
in a substantial number of DET in comparison to the 
control, with 311 and 209 genes, respectively (Figure 
2), the Volcano plots illustrated that the response to 
GMP was more extensive, with larger fold changes 
observed in differential expression overall. This find-
Figure 3. Volcano plots [−log10 P-value (y-axis) vs. log2 fold-change (x-axis)] demonstrating transcriptional changes following Bifidobacterium 
longum ssp. infantis exposure to (A) glycomacropeptide (GMP) and (B) periodate treatment of the GMP (GMP-P). Boxes highlight genes that 
were deemed as significantly changed following each treatment (fold change ≥1.5 and P ≤ 0.05). Color version available online.
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ing suggests that the oxidation of the GMP oligosac-
charides reduced the effect of GMP on B. longum ssp. 
infantis gene expression.
Effect of GMP Treatment on Carbohydrate- 
Related Genes
Glycomacropeptide treatment resulted in the up- 
and downregulation of genes involved in carbohydrate 
transport and metabolism (Table 1). Although several 
carbohydrate metabolism genes were also differentially 
expressed in response to GMP-P, the genes were differ-
ent to those upregulated in response to GMP-P and the 
fold change in expression was generally lower (Table 1). 
Several genes annotated as lacI regulatory genes were 
upregulated by both GMP and GMP-P. The lactose 
operon repressor (LacI) proteins can interact directly 
with DNA and inhibit expression of genes involved in 
lactose metabolism and the genes annotated as lacI 
genes in Table 1 may have a similar role in regulating 
sugar metabolism in B. longum ssp. infantis if func-
tional. Although unique lacI regulatory genes were 
differentially expressed in response to both treatments, 
those upregulated in the GMP-P group were induced 
to a much lesser extent. This differential induction of 
regulatory genes suggested that B. longum ssp. infantis 
may modulate its carbohydrate metabolism pathways 
in response to the GMP oligosaccharides.
Of the carbohydrate-related genes upregulated solely 
in response to GMP-P, the most significant were a 
β-galactosidase (Blon_2416) and an α-l-fucosidase 
(Blon_0248). The increased expression of a fucosidase 
gene was unexpected, as fucosylated GMP oligosaccha-
rides have only been detected in GMP isolated from 
Table 1. Carbohydrate-related genes: differentially regulated genes associated with carbohydrate metabolism
Locus tag  Annotated function  Treatment1 FC P-value
Blon_1571 Glycoside hydrolase, family 25 GMP 3.51 0.01
Blon_1831 Glycoside hydrolase, family 25 GMP 3.46 0.01
Blon_2415 Regulatory protein, lacI GMP 2.02 0.01
Blon_0139 4-α-Glucanotransferase GMP 1.98 0.02
Blon_1480 Extracellular solute-binding protein, family 5 (potential O-linked glycan 
utilization cluster)
GMP 1.87 0.04
Blon_0070 Glycogen/starch/α-glucan phosphorylase GMP 1.73 0.02
Blon_0874 Regulatory protein, lacI GMP 1.6 0.02
Blon_0137 α-Amylase, catalytic region GMP 1.59 0.05
Blon_1019 O-Sialoglycoprotein endopeptidase GMP 1.56 0.02
Blon_2145 NLP/P60 protein (cell wall associated glycoside hydrolase) GMP 1.56 0.02
Blon_2171 UDP-glucose 4-epimerase GMP −1.53 0.02
Blon_0268 Glycoside hydrolase family 2, sugar binding GMP −1.54 0.03
Blon_1722 Fructose-6-phosphate phosphoketolase GMP −1.56 0.01
Blon_1745 Pyruvate kinase GMP −1.58 0.01
Blon_1905 β-glucosidase GMP −1.58 0.02
Blon_2063 Galactose-1-phosphate uridylyltransferase GMP −1.63 0.02
Blon_2380 Extracellular solute-binding protein, family 1 (SBP for mannose 
oligosaccharides)
GMP −1.65 0.03
Blon_0881 Glucosamine-6-phosphate isomerase (nagB) GMP −1.67 0.04
Blon_2175 Binding-protein-dependent transport systems inner membrane component 
(LNB/GNB metabolism cluster)
GMP −1.75 0.03
Blon_0540 Lactaldehyde reductase GMP −1.8 0.01
Blon_0646 Glycosyl hydrolase, BNR repeat-containing protein (sialic acid utilization 
cluster)
GMP −1.92 0.03
Blon_2176 Binding-protein-dependent transport systems inner membrane component 
(LNB/GNB metabolism cluster)
GMP −1.99 0.02
Blon_1714 Pyruvate formate-lyase activating enzyme GMP −2.2 0
Blon_0640 PfkB domain protein (sialic acid utilization cluster) GMP −2.24 0
Blon_1715 Formate acetyltransferase GMP −2.32 0
Blon_2174 Hypothetical protein Blon_2174 (LNB/GNB metabolism cluster) GMP −2.34 0.00
Blon_2416 β-galactosidase GMP-P 1.91 0.03
Blon_0248 α-L-fucosidase GMP-P 1.8 0.05
Blon_0821 Carbohydrate kinase, FGGY GMP-P 1.6 0.02
Blon_0431 Sugar transporter GMP-P 1.58 0.01
Blon_2057 Periplasmic binding protein/lacI transcriptional regulator GMP-P 1.56 0.03
Blon_0208 6-Phosphogluconolactonase GMP-P 1.55 0.02
Blon_0621 Glucan 1,3-β-glucosidase GMP-P 1.54 0.02
Blon_0516 Regulatory protein, lacI GMP-P 1.51 0.03
1GMP = bovine milk glycomacropeptide; GMP-P = periodate treatment of the GMP; FC = fold change; UDP = uridine diphosphate glucose; 
SBP = solute binding protein; LNB/GNB = lacto-N-biose/galacto-N-biose; BNR = bacterial neuraminidase repeat.
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colostrum to date (Fournet et al., 1975) and mature 
milk was the source of the GMP used here. In addition, 
GMP-P was periodate treated, so intact fucose residues 
should not be present, regardless of whether they were 
present or not before periodate treatment. The expres-
sion of an α-l-fucosidase in B. longum ssp. infantis dur-
ing growth on inulin, a nonfucose-containing substrate, 
has previously been reported also (Kim et al., 2013). 
The expression of β-galactosidase (Blon_2416) was also 
increased in the GMP group (fold change = 1.65), but 
was not statistically significant (P = 0.07). However, 
numerous genes in close proximity to Blon_2416 on the 
chromosome were also upregulated following growth in 
GMP (Blon_2415, Blon_2419-Blon_2423; Supplemen-
tal Table S2, https:// doi .org/ 10 .3168/ jds .2018 -14499), 
including a lacI regulatory gene.
Expression of 3 genes related to sucrose and starch 
metabolism were upregulated following exposure to 
GMP only; Blon_0070, Blon_0137 and Blon_0139. 
These genes may be involved in the metabolism of 
glucose present in the growth media. Their increased 
expression following exposure to GMP could result in 
an increased metabolism of glucose from the environ-
ment and contribute to the observed growth increase. 
Interestingly, Blon_0139 was also upregulated follow-
ing exposure of B. longum ssp. infantis to a mixture of 
3′- and 6′-sialyllactose (Kavanaugh et al., 2013). The 
presence of a possible O-linked oligosaccharide utiliza-
tion gene cluster on the B. longum ssp. infantis genome 
was previously predicted (Garrido et al., 2013a) and 
comprised Blon_1479, an α-N-acetylgalactosaminidase 
homolog, and Blon_1480, an ABC transporter for pep-
tide importation. In the present study, Blon_1480 was 
highly upregulated in response to growth in the presence 
of GMP whereas Blon_1479 expression was unaffected. 
As GMP is characterized by highly sialylated O-linked 
oligosaccharides, it may be recognized by Blon_1480 
for import. Furthermore, the gene Blon_1019 was also 
upregulated following growth in the presence of GMP 
and it has a predicted function in the metabolism of 
O-glycosylated peptides as an O-sialoglycoprotein en-
dopeptidase.
Two candidate sialidase genes have previously been 
identified within the B. longum ssp. infantis genome, 
Blon_0646 and Blon_2348, which appear to be intracel-
lular (Sela et al., 2008). The first gene is present in a 
gene cluster dedicated to sialic acid metabolism, which 
provides N-acetyl glucosamine-6-P for further process-
ing into fructose-6-P to enter central metabolism (Sela 
et al., 2011). Blon_0646 was downregulated in the 
GMP group in addition to related genes, Blon_0640, 
Blon_1722 (fructose-6-P phosphoketolase), Blon_1745 
(pyruvate kinase), and Blon_0881 (nagB). For degrada-
tion of HMO, B. longum ssp. infantis deploys a utiliza-
tion strategy involving translocation of intact oligosac-
charides using ABC transporters. Once internalized, 
milk oligosaccharides are degraded by several intracel-
lular glycosyl hydrolases that target linkages inherent 
to HMO. Released monosaccharides are fermented in 
the central fructose-6-phosphate phosphoketolase path-
way (bifid shunt), resulting in the production of ATP 
and secretion of acetate and lactate as end-products 
(Garrido et al., 2015). Given that GMP is a more com-
plex carbohydrate source, it may be that B. longum 
ssp. infantis diverts some of its energy into producing 
the solute binding proteins and glycosyl hydrolases re-
quired for degradation of GMP at the expense of the 
simpler disaccharide and monosaccharide metabolism 
during this phase of growth. When grown on complex 
carbohydrates, bifidobacteria may improve their fitness 
if able to use such sources, despite the lower growth 
rate when compared with simple carbohydrates.
A recent study by Karav et al. (2016) on N-linked 
glycoproteins from whey supports this hypothesis. 
Here, B. longum ssp. infantis ATCC 15697 did not grow 
on the deglycosylated milk protein fraction, clearly 
demonstrating that the glycan portion of the milk gly-
coproteins provided the key substrate for growth. The 
authors found that an endoglycosidase (EndoBI-1) is 
first required to carry out the initial deglycosylation 
and that EndoBI-1 expression is based on the gly-
can portion of the glycoprotein. Given that free milk 
oligosaccharides do not induce EndoBI-1 expression 
(Garrido et al., 2015), this suggests that B. longum 
ssp. infantis senses intact glycoprotein and induces 
EndoBI-1 in response. As GMP is O-glycosylated, up-
regulation of O-endoglycosidase(s) such as Blon_1019 
would be expected. The fact that no change in regu-
lation of the other sialidase, Blon_2348, or in genes 
such as Blon_2016 (β-galactosidase) was observed in 
the presence of GMP may not be surprising, as these 
enzymes that have been linked with the degradation of 
free glycans (HMO; Garrido et al., 2012a).
Interestingly, expression of several other genes 
related to simple sugar and free oligosaccharide 
metabolism, such as members of the lacto-N-biose 
(LNB) and galacto-N-biose (GNB) metabolism cluster 
(Blon_2171-Blon_2177; LoCascio et al., 2010), were 
downregulated in the GMP-treated group. The down-
regulation of the same genes in the LNB/GNB cluster 
(Blon_2174-Blon-2176) was previously described fol-
lowing exposure of B. longum ssp. infantis to 3′- and 
6′-sialyllactose (Kavanaugh et al., 2013). No significant 
transcriptional changes were observed on the 43-kbp 
cluster at Blon_2331-Blon_2361, which are dedicated 
to the import and processing of HMO (Sela et al., 2008). 
Journal of Dairy Science Vol. 101 No. 8, 2018
BIFIDOBACTERIUM RESPONSE TO GLYCOMACROPEPTIDE 9
Downstream of this genome region, a large number of 
genes were differentially expressed in the GMP-treated 
group, including upregulation of Blon_2370-Blon_2373, 
involved in bacterial growth, and downregulation of 
transport-related Blon_2379-Blon_2380. Again, a simi-
lar effect was previously observed following exposure to 
3′- and 6′-sialyllactose (Kavanaugh et al., 2013).
Two genes encoding glycoside hydrolases from family 
25 (GH25), Blon_1571 and Blon_1831, were upregu-
lated in response to GMP. Family 25 has only 1 docu-
mented function to date, as a lysozyme involved in cell 
wall and peptidoglycan catabolism, and may thus have 
a role in facilitating cell division and in defense. When 
the whole-genome transcription plots were considered, 
large peaks in the GMP-exposed cells were observed 
in the vicinity of both significant GH25 (Supplemental 
Figure S1 https:// doi .org/ 10 .3168/ jds .2018 -14499). 
When these genetic loci were studied in more detail, 
clusters of substantial homology were identified. The 
cluster at Blon_1546 – Blon_1571 (cluster A) had a 
larger number of genes displaying increased expression, 
with the highest overall upregulation observed for hy-
pothetical genes at this locus. Fibronectin type III do-
main proteins (Fn3) were also present in both clusters 
downstream of the GH25 (Blon_1563 and Blon_1825). 
Both Fn3 proteins were also upregulated in response to 
GMP, as were several other hypothetical genes in the 
clusters. The Fn3 domains have previously been de-
scribed in several bacterial glycoside hydrolases (Little 
et al., 1994; da Silva et al., 2014). These domains may 
have a role in the degradation of insoluble substrates 
and may have been acquired by bacteria through hori-
zontal gene transfer from animals (da Silva et al., 2014).
A BLAST search (https:// blast .ncbi .nlm .nih .gov/ 
Blast .cgi) for similar Fn3 proteins identified 2 other 
bifidobacteria-containing gene arrangements similar to 
cluster A of B. longum ssp. infantis. Bifidobacterium 
breve DSM20213 had just 1 region of homology with a 
Fn3 protein at locus BIFBRE_01730, whereas Bifido-
bacterium adolescentis L2–32 contained 2 duplicates of 
the cluster with Fn3 proteins at loci BIFADO_01393 
and BIFADO_01092. The GH25 hydrolases were only 
present in the clusters identified in B. longum ssp. in-
fantis, and only the genes encoding for Fn3 protein and 
both flanking genes showed homology across all 5 do-
mains (Figure 4). A BlastX (https:// blast .ncbi .nlm .nih 
.gov/ Blast .cgi ?LINK _LOC = blasthome & PAGE _TYPE 
= BlastSearch & PROGRAM = blastx) analysis revealed 
all Fn3 proteins shared ≥ 50% identity (Supplemen-
tal Table S3 https:// doi .org/ 10 .3168/ jds .2018 -14499). 
Clustal analysis revealed large areas of homology be-
tween all 5 Fn3 proteins at the N- and C-termini, in-
cluding the fibronectin type III domain. These genome 
comparisons suggest that some bifidobacteria may 
contain gene clusters that allow them to use complex 
glycopeptide substrates such as GMP.
Figure 4. Comparison of clusters identified in Bifidobacterium containing fibronectin type III domain proteins. Each solid arrow indicates an 
open reading frame (ORF) and arrow length is proportional to the length of the predicted ORF. Locus tags are indicated at the beginning and 
end of areas of homology and arrow color indicates annotated function. The AA identity of each predicted protein is indicated as a percentage 
relative to its equivalent protein encoded by Bifidobacterium longum ssp. infantis ATCC 15697 in the cluster present at locus tags blon_1548 – 
blon_1572 (white shading = 25–50% identity, light gray shading = 50–70% identity, dark gray shading = >70% identity).
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Gene Expression Validation by RT-qPCR
Due to the high similarity between the genes in the 
both GH25 clusters, RT-qPCR was performed to verify 
both clusters were upregulated and eliminate the pos-
sibility of cross-hybridization on the array resulting in 
false positives. Here, the expression levels of the 16S 
rRNA gene did not vary significantly between samples 
(data not shown) and was therefore proven to be a 
valid choice as a reference gene. The high similarity be-
tween both GH25 genes made it difficult to use primer-
based methods to selectively analyze their expression. 
Therefore, flanking genes, including the genes encod-
ing for the Fn3 proteins, were selected for RT-qPCR 
analysis and confirmed the upregulation of the larger 
cluster as observed in the microarray (Table 2). The 
RT-qPCR also confirmed the upregulation of the Fn3 
gene (Blon_1825) in the smaller cluster.
CONCLUSIONS
The introduction of bovine GMP lead to a significant 
increase in the growth of the infant-associated strain, 
B. longum ssp. infantis. This effect was substantially 
reduced following periodate oxidation of the conjugated 
oligosaccharides. The inclusion of GMP as a functional 
ingredient may influence the predominance of beneficial 
bacteria in the gut. The effect was observed when B. 
longum ssp. infantis was cultured in a nutritionally com-
plex environment; however, it will be key to determine 
if this growth promotion effect is evident in a mixed 
bacterial population as would occur in vivo. Treat-
ment with GMP induced some glycogenes whereas it 
appeared to repress others, and these data suggest that 
the response of B. longum ssp. infantis to glycosylated 
substrates is a tightly regulated response and exposure 
to a specific glycan presentation elicits a highly spe-
cialized response. The transcriptional response may be 
divided into 3 quite distinct components: transport of 
extracellular molecules, glycan metabolism, and growth 
and cell division. It is likely that the transport and 
metabolism genes are specific to the GMP oligosaccha-
rides whereas the growth and cell division response are 
likely to be general responses to increased growth rate. 
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